BPMC Director Gets 3,902 RSUs; Ownership Rises to 12,644 Shares

Blueprint Medicines Corporation (BPMC) – SEC Form 4 Insider Transaction Director John Tsai reported the receipt of 3,902 restricted stock units (RSUs) on 18 June 2025.

Rhea-AI Filing Summary

Blueprint Medicines Corporation (BPMC) – SEC Form 4 Insider Transaction

Director John Tsai reported the receipt of 3,902 restricted stock units (RSUs) on 18 June 2025. Each RSU represents one share of BPMC common stock and vests 100 % on the earlier of 18 June 2026 or the company’s next annual shareholders’ meeting. The grant was recorded at an indicated price of $128.12 per share, a value reference supplied within the Form 4. Following the award, Tsai’s total direct beneficial ownership stands at 12,644 shares.

No open-market purchases or sales, option exercises, or derivative transactions were disclosed. The filing indicates a routine equity compensation grant intended to align the director’s interests with those of shareholders.

Positive

• Director ownership increases by 3,902 shares through RSU grant, modestly tightening alignment with shareholder interests.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine RSU grant; minor increase in insider ownership, limited market impact.

The Form 4 shows a standard equity compensation transaction: 3,902 RSUs issued to Director John Tsai, vesting in roughly one year or at the next AGM. Post-grant ownership is 12,644 shares, a modest stake that marginally strengthens alignment but does not signal a deliberate open-market purchase. No sales or derivative activities are noted. Given the relatively small share count versus BPMC’s outstanding float and absence of price-sensitive information, the filing is best viewed as neutral from an investment perspective.

Insider Trade Summary

Grant/Award: 3,902 shares

Grant/Award 1 txn

Insider Tsai John

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,902	$128.12	$500K

Holdings After Transaction: Common Stock — 12,644 shares (Direct)

Footnotes (1)

1. F1. The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

FAQ

How many Blueprint Medicines (BPMC) shares did John Tsai acquire?

3,902 restricted stock units, each representing one common share.

When do the RSUs granted to John Tsai vest?

They vest 100 % on 18 June 2026 or at the next annual shareholder meeting, whichever occurs first.

What is John Tsai’s total BPMC share ownership after the transaction?

He now directly owns 12,644 shares.

Was this an open-market purchase by the director?

No. It was a restricted stock unit grant under the company’s compensation program.

What price was referenced for the RSU grant?

The Form 4 lists a price of $128.12 for the common stock underlying the RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tsai John

(Last) (First) (Middle)

45 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Blueprint Medicines Corp [ BPMC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		3,902(1)	A	$128.12	12,644	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

	/s/ Melissa Masse	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.